# A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

> **NCT04735822** · EARLY_PHASE1 · COMPLETED · sponsor: **Kadmon Corporation, LLC** · enrollment: 30 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Part 1: Belumosudil 40 mg/mL Sequence ABFCED
- **DRUG:** Part 1: Belumosudil 40 mg/mL Sequence BCADFE
- **DRUG:** Part 1: Belumosudil 40 mg/mL Sequence CDBEAF
- **DRUG:** Part 1: Belumosudil 40 mg/mL Sequence DECFBA
- **DRUG:** Part 1: Belumosudil 40 mg/mL Sequence EFDACB
- **DRUG:** Part 1: Belumosudil 40 mg/mL Sequence FAEBDC
- **DRUG:** Part 2: Belumosudil 200 mg Sequence GHI
- **DRUG:** Part 2: Belumosudil 200 mg Sequence HIG
- **DRUG:** Part 2: Belumosudil 200 mg Sequence IGH
- **DRUG:** Part 2: Belumosudil 200 mg Sequence IHG
- **DRUG:** Part 2: Belumosudil 200 mg Sequence GIH
- **DRUG:** Part 2: Belumosudil 200 mg Sequence HGI

## Key facts

- **NCT ID:** NCT04735822
- **Lead sponsor:** Kadmon Corporation, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-26
- **Primary completion:** 2021-09-03
- **Final completion:** 2021-09-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04735822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04735822, "A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04735822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*